Authors
Latest:
Dr. Kansagra on Updates With CAR T-Cell Therapy in Hematologic CancersAnkit Kansagra, MD, discusses key updates with CAR T-cell therapy in hematologic cancers.
Latest:
CAR T-Cell Research SurgesHundreds of trials are under way, 3 CAR T-cell therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma.
Latest:
Dr. Sauter on Off-The-Shelf Versus Autologous CAR T-Cell Products in Hematologic MalignanciesCraig Sauter, MD, discusses the differences between off-the-shelf and autologous chimeric antigen receptor T-cell products in patients with hematologic malignancies.
Latest:
Expert Highlights Efficacy of KTE-C19 CAR T-Cell Therapy in Non-Hodgkin LymphomaKTE-C19, an investigational CAR T-cell therapy, recently demonstrated positive results for patients with chemorefractory aggressive non-Hodgkin lymphoma.
Latest:
Dr. Chaudhary on Short-Term and Long-Term Future of CAR T-CellsPreet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the short-term and long-term future of CAR T-cells.
Latest:
Long Term Follow-Up of Axi-Cel in R/R Non-Hodgkin Lymphoma : Sattva S. Neelapu, MDThe professor from The University of Texas MD Anderson Cancer Center discussed long-term follow-up analysis of the phase 2 ZUMA-5 trial.
Latest:
Dr. Garfall Discusses CAR T-Cell Therapy in Multiple MyelomaAlfred L. Garfall, MD, MS, discusses the potential of CAR T-cell therapy in multiple myeloma.
Latest:
Novel Treatments for Multiple Myeloma: C. Ola Landgren, MD, PhDThe inaugural leader of the Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center, University of Miami discussed exciting novel therapeutic approaches in multiple myeloma.
Latest:
CAR T-Cell Therapy Starts to Enter MCL SpaceFrederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.
Latest:
Future of MCL Treatment May Lie in Combinations, CAR T-Cell TherapyRobert Dean, MD, discusses the promise for new therapies in mantle cell lymphoma.
Latest:
Dr. Smith Discusses CAR T Cell Persistence in MyelomaEric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.
Latest:
Dr. Papa on the Impact of CAR T Cell Trial in Head and Neck CancerSophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses the impact of a recent study of chimeric antigen receptor (CAR) T cells in head and neck squamous cell carcinoma.
Latest:
Findings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALLLow disease burden prior to treatment with CD19-specific chimeric antigen receptor T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia.
Latest:
Integrating Ide-Cel Into Pretreated Multiple Myeloma Regimens: Shaji Kumar, MDThe hematologist from Mayo Clinic discussed the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.
Latest:
Selecting CAR T-Cell Therapies for R/R DLBCLExperts discuss the use and selection of CAR T therapies in relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Bijal Shah, MD, on AUTO1 in R/R B-Cell ALL and the FELIX TrialShah explained that the trial is unique due to its inclusion of patients with MRD–positive B-ALL.
Latest:
Dr. Usmani Discusses CAR T-Cell Therapy in Multiple MyelomaSaad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses CAR T-cell therapy in multiple myeloma.
Latest:
Dr. Bauml on CAR T-Cell Therapy in Head and Neck CancerJoshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses CAR T-cell therapy in head and neck cancer.
Latest:
Speakers Suggest Moving Newer Agents Into Earlier Lines in MMBispecific T-cell engagers and chimeric antigen receptor T-cell therapies seem destined to move into earlier lines of therapy for multiple myeloma (MM), speakers at the European Hematology Association 2021 Virtual Congress said.
Latest:
Dr. Maloney on the Value of CAR T Cells in Relapsed/Refractory Aggressive LymphomasDavid G. Maloney, MD, PhD, discusses the value of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive lymphomas.
Latest:
Dr. Winter on the Promise of CAR T-Cell Therapy in Hematologic MalignanciesJane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the promise of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.
Latest:
Monitoring and Support for Patients Receiving CAR T-Cell TherapyExperts discuss providing supportive care to patients receiving CAR T-cell therapy.
Latest:
Dr. Daver on CAR T-Cell Therapy Approval in Pediatric ALLNaval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia.
Latest:
Dr. Epperla on CAR T-Cell Therapy in MCLNarendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).
Latest:
Dr. Maloney on Targets for CAR T-Cell TherapyDavid Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the success and challenges of chimeric antigen recptor (CAR) T-cell therapy in hematologic malignancies.
Latest:
Dr. Andreadis on CAR T-Cell Therapy in Relapsed/Refractory MCLCharalambos (Babis) Andreadis, MD, MSCE, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.
Latest:
Dr. Berdeja Discusses Response to CAR T-Cell Therapy bb2121Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.
Latest:
Dr. Coutre Discusses Challenges With CAR T-Cell Therapy in ALLSteven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia.
Latest:
Dr. Perl on Challenges of Implementing Immunotherapy in AMLAlexander E. Perl, MD, MS, discusses the challenges of using immunotherapy with antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies in acute myeloid leukemia.
